Last €2.25 EUR
Change Today +0.073 / 3.36%
Volume 242.2K
PA8 On Other Exchanges
As of 1:20 PM 10/23/14 All times are local (Market data is delayed by at least 15 minutes).

paion ag (PA8) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/26/14 - €4.47
52 Week Low
10/24/13 - €0.73
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PAION AG (PA8)

Related News

No related news articles were found.

paion ag (PA8) Related Businessweek News

No Related Businessweek News Found

paion ag (PA8) Details

PAION AG, together with its subsidiaries, operates as a biopharmaceutical company that develops and commercializes drug candidates for diseases or interventions. The company’s portfolio of drug candidates include Remimazolam, a short-acting general anaesthetic/sedative agent that is in Phase-III clinical trials for the treatment of anaesthesia and procedural sedation, as well as in Phase-II clinical trials for ICU sedation. Its drug candidates also comprise Solulin, a variant of the human protein thrombomodulin in Phase-I clinical trials to stabilize the initial fibrin clot to stop bleeding; PN 13, a thrombomodulin mutant in preclinical stage to treat haemophilia and hyperfibrinolysis; and GGF2, a glial growth factor 2 that has completed Phase-I clinical trials to stimulate the growth and differentiation of various cells, including glial cells to demyelinate diseases, such as multiple sclerosis, damage of the myelin sheath, and degeneration of nerve cells. The company was founded in 2000 and is headquartered in Aachen, Germany.

15 Employees
Last Reported Date: 08/8/14
Founded in 2000

paion ag (PA8) Top Compensated Officers

Co-Founder, Chairman of Management Board and ...
Total Annual Compensation: €383.2K
Co-Founder, Chief Medical Officer and Member ...
Total Annual Compensation: €352.1K
Compensation as of Fiscal Year 2013.

paion ag (PA8) Key Developments

Paion AG - Special Call

Paion AG - Special Call

Paion AG - Special Call

To explain the current state of discussion with the Japanese partner ONO Pharmaceutical

Paion AG Grants License to Yichang Humanwell for M6G in China

Paion AG and Yichang Humanwell Pharmaceutical Co. Ltd. announced that they have entered into a license agreement for M6G which gives Yichang an exclusive licence under PAION's know-how regarding M6G for the development, manufacture and commercialization in the territory of People's Republic of China. By concluding the license PAION receives payments totaling EUR 1.6 million. EUR 0.8 million is due through today's signing of the license agreement. The remaining payments are due upon reaching certain development milestones in the next 1.5 years. Yichang intends to develop and commercialize M6G for peri-operative pain for the Chinese Market.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PA8:GR €2.25 EUR +0.073

PA8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PA8.
View Industry Companies

Industry Analysis


Industry Average

Valuation PA8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.8x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PAION AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at